Scarica l'app Stockscreener
0.4901
3.90%
-0.0199
Dopo l'orario di chiusura:
.49
-0.000100
-0.02%
Precedente Chiudi:
$0.51
Aprire:
$0.4403
Volume 24 ore:
207.33K
Relative Volume:
0.05
Capitalizzazione di mercato:
$13.89M
Reddito:
-
Utile/perdita netta:
$-4.23M
Rapporto P/E:
-3.2827
EPS:
-0.1493
Flusso di cassa netto:
$-10.48M
1 W Prestazione:
-4.11%
1M Prestazione:
+4.72%
6M Prestazione:
-38.74%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.4403
$0.5284
Intervallo di 1 settimana:
$0.436
$0.543
Portata 52W:
$0.262
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Nome
Curanex Pharmaceuticals Inc
Settore
Industria
Telefono
718-673-6078
Indirizzo
2 JERICHO PLAZA,, JERICHO
Compare CURX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.4901 | 13.89M | 0 | -4.23M | -10.48M | -0.1493 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Curanex Pharmaceuticals Inc Borsa (CURX) Ultime notizie
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases - MSN
Curanex Pharmaceuticals Inc (CURX) stock price, news, quote and history - Yahoo Finance UK
Top Curanex Pharmaceuticals (CURX) Competitors 2026 - marketbeat.com
Curanex Pharmaceuticals Inc (CURX) latest stock news and headlines - Yahoo Finance Singapore
Curanex Pharmaceuticals Inc (CURX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Curanex adds cancer cachexia to drug development pipeline - Investing.com
Curanex Pharmaceuticals Expands Drug Development Pipeline - TradingView
Curanex Adds Cancer Cachexia to Core Drug Pipeline - tipranks.com
Curanex (Nasdaq: CURX) targets cancer cachexia in expanded pipeline - Stock Titan
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company - The Manila Times
Curanex adds cancer cachexia to drug development pipeline By Investing.com - Investing.com UK
No U.S.-approved treatment exists for cancer cachexia. Curanex adds it - Stock Titan
Curanex Pharmaceuticals and Phyto-N: Botanical Drug Development for Inflammatory Diseases, COVID-19, Diabetes, NAFLD, and Gout 33 - Minichart
Curanex Advances Phyto-N Toward IND Submission in 2026 Annual Report - National Today
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission - Bitget
CURX: IPO proceeds fund R&D for Phyto-N; no revenue, $4.2M net loss, and internal control weaknesses - TradingView
Curanex Pharmaceuticals Inc Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Curanex Pharmaceuticals (NASDAQ: CURX) outlines multi-disease Phyto-N drug strategy - Stock Titan
Ulcerative colitis drug candidate stays on track for late-2026 filing - Stock Titan
CURX Ownership | CURANEX PHARMACEUTICALS INC (NASDAQ:CURX) - ChartMill
What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours - MSN
Stock List: Research Stocks from Around the World - GuruFocus
CURANEX PHARMACEUTICALS INC (CURX) Fundamental Analysis & Valuation - chartmill.com
CURX Should I Buy - Intellectia AI
Nasdaq tumbles over 350 points; US initial jobless claims increase - MSN
Curanex Pharmaceuticals IncTargets Ind Submission For Phyto-N In Q4 2026 - TradingView
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission - Yahoo Finance
Botanical drug used in China for 30 years clears key U.S. safety test - Stock Titan
Curanex adds two pharmaceutical veterans to advisory board By Investing.com - Investing.com Nigeria
Curanex adds two advisors to scientific board ahead of IND filing By Investing.com - Investing.com India
Curanex adds two advisors to scientific board ahead of IND filing - Investing.com Australia
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers - Bitget
TB and COVID scientists join Curanex board to steer 2026 trial plans - Stock Titan
Curanex adds two pharmaceutical veterans to advisory board - Investing.com India
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board - marketscreener.com
Veteran drug creators with HIV, HCV medicines join Curanex - Stock Titan
Curanex Formalizes Long-Term Executive Employment and Compensation Agreements - TipRanks
Curanex Pharmaceuticals Inc Enters into Executive Employment Agreement with Jun Liu as President and Chairman of the Board, Effective March 1, 2026 - marketscreener.com
[8-K] Curanex Pharmaceuticals Inc Reports Material Event - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Curanex Forms World Class Scientific Advisory Board - Bitget
Curanex Pharmaceuticals Inc (CURX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Stocks in the News: ALBT, NDRA, CURX, HCTIAI, Clinical Milestones Drive Market Surges - marketscreener.com
Market Movers | Winners: IXHL, ALBT, RXT | Losers: THRY, EOSE, ERII - Trefis
Thursday's session: most active stocks - ChartMill
Unusual volume stocks are being observed in Thursday's session. - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Curanex Pharmaceuticals Inc Azioni (CURX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):